ASH 2010 News Coverage

ASH 2010

First-Line Bendamustine in the Treatment of Chronic Lymphocytic Leukemia Demonstrates Efficacy vs Chlorambucil Without Compromising Quality of Life

Bendamustine (BEN) should be considered a “backbone” drug in first-line chemotherapy of patients with advanced chronic lymphocytic leukemia (CLL) due to its significantly greater efficacy compared with chlorambucil (CLB) with no compromise to quality of life (QoL) in this older and potentially comorbid population, follow-up data from the registration trial has found. The data was presented at the 52nd American Society of Hematology Annual Meeting and Exposition.

Safety and Efficacy of the mTOR Inhibitor Everolimus As Early Interventional Replacement for Calcineurin Inhibitors (CNI) in Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation

The use of everolimus, a mammalian target of rapamycin (mTOR) inhibitor, is feasible and efficacious for the prevention of graft-versus-host disease (GVHD) in a series of patients after allogeneic stem cell transplantation (SCT), according to a study presented at the 52nd American Society of Hematology Meeting and Exposition..

Treating Follicular Lymphoma Patients Initially With First-Line Rituximab Delays Time to Initiation of New Therapy

Recent findings may change the management of patients with asymptomatic, advanced-stage follicular lymphoma (FL): initial treatment with rituximab was found to delay significantly the need for new therapy, reported Kirit M. Ardeshna, MD, of the University College London Hospitals, London, UK. The study was presented at the 52nd American Society of Hematology Annual Meeting and Exposition.

Appropriate Selection of Treatment Modalities and Knowledge About the Biology of Pediatric Malignancies Are Key to Treatment

The appropriate selection of treatment modalities for children with hematologic malignancies and a careful understanding of the biology of each disorder and the results of each therapy are key to treating these conditions in the pediatric population, according to three presenters who spoke at the Pediatric Malignancies education program at the 52nd American Society of Hematology Meeting and Exposition.

Clinical Advances in Hodgkin Lymphoma

According to the American Cancer Society, approximately 8,500 people will be diagnosed with Hodgkin’s lymphoma in the United States during 2010. Despite the overall favorable prognosis of Hodgkin’s lymphoma, efforts to improve therapy for high-risk patients and to decrease long-term toxicity for low-risk patients continue. New methods of risk stratification, including FDG-PET and molecular profiling, as well as new therapies with non-overlapping toxicity profiles, have made these goals a reality.

Diversity of Genetic and Epigenetic Events Leading to Malignant Transformation: Unifying Themes for the Effective Management of Solid Tumor and Hematologic Malignancies

The ASH/ASCO Joint Symposium, held today at the 52nd American Society of Hematology Annual Meeting and Exposition, focused on the understanding of the various genetic and epigenetic events that lead to malignant transformation and solid tumor/hematologic malignancies and discussed novel therapies that selectively target those events.

Advances in Care for Patients With Myelodysplastic Syndromes

A number of recent advances have been made that will improve the care of patients with myelodysplastic syndromes (MDS), including new developments in prognosis, the use of allogeneic transplantation, and endpoints in the management of patients with MDS. The findings were presented by three researchers during an education program presented at the 52nd American Society of Hematology Meeting and Exposition.

Iron Supplementation of Erythropoiesis-Stimulating Agents Increases Hematopoietic Response Rates in Patients With Cancer and Chemotherapy-Induced Anemia

When compared with using erythropoiesis-stimulating agents (ESA) alone or placebo, iron supplementation of ESAs significantly increases hematopoietic response rates and reduces the number of red blood cell (RBC) transfusions in patients with chemotherapy-induced anemia (CIA), results of the first systematic review and meta-analysis have found. The study was presented at the 52nd American Society of Hematology Annual Meeting and Exposition.

Bendamustine + Prednisolone + Lenalidomide Well Tolerated in Patients With Refractory or Relapsed Multiple Myeloma

Bendamustine, prednisolone, and lenalidomide (RBP) was well tolerated in patients with relapsed or refractory multiple myeloma in whom maximum tolerated dose (MTD) had not been reached, results of a phase 1 feasibility and safety study presented at the 52nd American Society of Hematology Annual Meeting and Exposition have shown.

Oral Lenalidomide, Cyclophosphamide, and Prednisone (RCP): Preliminary Results Suggest “Excellent” Activity in Patients With Newly Diagnosed Multiple Myeloma

Initial analysis of the first evaluable patients with newly diagnosed multiple myeloma enrolled in a phase 2 study has found the combination of lenalidomide, cyclophosphamide, and prednisone (RCP) to have “excellent” activity, with manageable overall toxicities. The study was presented at the 52nd American Society of Hematology Annual Meeting and Exposition.